Back to results
US 10,501,557 B2Granted
Mutated immunoglobulin-binding polypeptides
AssigneeGE Healthcare BioProcess R&D AB
InventorsGustav Rodrigo, Tomas Bjorkman, Mats Ander
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeGE Healthcare BioProcess R&D AB
InventorsGustav Rodrigo, Tomas Bjorkman, Mats Ander
Estimating the term…
An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
An Fc-binding polypeptide comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA) wherein the polypeptide is selected from the group consisting of SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:16, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:44, SEQ ID NO:46, and SEQ ID NO:48, and wherein the mutant binds the Fc domain of an antibody and has improved alkaline stability compared to SEQ ID NO:
Dependencies are inferred from the claim text.